The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented
long-term clearance of relapse/refractory hematological malignancies in both pediatric and …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Chimeric antigen receptor (CAR) T cells have not induced meaningful clinical responses in
solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during …

Cancer immunotherapy harnesses the body's immune system to combat malignancies,
building upon an understanding of tumor immunosurveillance and immune evasion …

Tumour-associated neutrophils can exert antitumour effects but can also assume a pro-
tumoural phenotype in the immunosuppressive tumour microenvironment. Here we show …

CAR-T cells are widely recognized for their potential to successfully treat hematologic
cancers and provide durable response. However, severe adverse events such as cytokine …

Chimeric antigen receptor (CAR) T-cell therapy has achieved substantial clinical outcomes
for tumors, especially for hematological malignancies. However, extending the duration of …

Chimeric antigen receptor T (CAR-T) cell therapy may achieve long-lasting remission in
patients with B-cell malignancies not responding to conventional therapies. However …

Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in
immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face …

New drug modalities offer life-saving benefits for patients through access to previously
undruggable targets. Yet these modalities pose a challenge for the pharmaceutical industry …